title: [Monotherapy with the ACE-inhibitor ramipril or the calcium antagonist nitrendipine in essential hypertension].
abstract: Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists have, by reason of their potentially favourable pharmacological profile, become increasingly established in the treatment of hypertension in recent years. In a double-blind randomized study with an initial placebo phase, carried out by practising physicians and thus aimed at the "usual" practice patients with essential hypertension, we assessed (1) the antihypertensive effect and tolerability of an ACE inhibitor (ramipril, 5 mg/d) or a calcium antagonist (nitrendipine, 20 mg/d) given in a single daily dose, and (2) a possible age-dependent blood pressure (BP) effect of these therapies. In the 4 weeks' placebo phase, the two treatment groups were comparable as regards average age (49.6 and 49.4 years), age-range (27-67 and 25-64 years) and BP. Fifty-two patients completed the following 6 weeks' phase with active drug therapy. On ramipril (n = 26), the BP measured 24-25 hours after the last drug administration was reduced in the supine position from an average of 155/102 to 142/91 mmHg (mean reduction -10.1%) and in the upright position from 156/106 to 141/96 mmHg (-9.3%). Nitrendipine (n = 26) reduced the average BP from 155/102 to 147/94 mmHg (-6.8%) and from 155/106 to 146/99 mmHg (-6.6%) respectively. BP-lowering effects of both treatments were largely independent of age. Including the patients who discontinued the study prematurely because of side effects (1 on ramipril, 4 on nitrendipine), the "intention to treat analysis" shows BP normalization rates (diastolic < or = 90 mm Hg) of 55% (ramipril) and 30% (nitrendipine) respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Universitäts-Poliklinik Bern.
authors.forename: P
authors.initials: P
authors.lastname: Weidmann
authors.forename: J
authors.initials: J
authors.lastname: Frank
authors.forename: W
authors.initials: W
authors.lastname: Graf
authors.forename: R
authors.initials: R
authors.lastname: Hausammann
authors.forename: T
authors.initials: T
authors.lastname: Heuberger
authors.forename: P
authors.initials: P
authors.lastname: Kerkhoven
authors.forename: G
authors.initials: G
authors.lastname: Probst
authors.forename: P
authors.initials: P
authors.lastname: Schudel
authors.forename: C
authors.initials: C
authors.lastname: Steinbach
authors.forename: A
authors.initials: A
authors.lastname: Müller
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000009:adverse effects / Q000627:therapeutic use*; D017257:Ramipril / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D009568:Nitrendipine; D017257:Ramipril
vernacular_title: Monotherapie mit dem ACE-Hemmer Ramipril oder dem Calcium-Antagonisten Nitrendipin bei essentieller Hypertonie.